[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-screening":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,73,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100564195","phase-3-screening-for-prostate-cancer-using-high-resolution-micro-ultrasound-versus-multiparametric-magnetic-resonance-imaging-100564195",false,"NCT06626022","Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.","A Phase 3, Multicenter, International, Non-inferiority, Randomized Clinical Trial Comparing Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging (MUSIC-Screen)","MUSIC-Screen","Inclusion Criteria:\n\n1. Male sex;\n2. Age 50-70;\n3. PSA 3-20 and\u002For abnormal DRE;\n4. Biopsy naïve.\n\nExclusion Criteria:\n\n1. Prior personal history of prostate cancer;\n2. Prior prostate imaging using microUS or MRI;\n3. Contraindication to microUS or MRI;\n4. Testosterone replacement therapy within last 12 months; or\n5. Androgen deprivation therapy within last 12 months.",true,"MALE","50 Years","70 Years",{"count":22,"type":23},1284,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.",[29],"Prostate Cancer Screening","RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2025-05-08",{"date":38,"type":23},"2029-11-30",{"name":40,"class":41},"University of Alberta","OTHER",9,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100587074","psma-petmri-guided-prostate-biopsy-for-pi-rads-3-and-prior-negative-biopsy-100587074","NCT06923657","PSMA PET\u002FMRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy","Application of PSMA PET\u002FMRI-guided Prostate Targeted Biopsy in Patients With PI-RADS ≤ 3 and Negative Previous Biopsy: A Single-center, Prospective, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Serum PSA \\> 4 ng\u002FmL\n* At least one prior negative prostate biopsy\n* At least two consecutive increases in PSA and\u002For PHI\n* Negative digital rectal examination\n* Multiparametric MRI (mpMRI) indicating a PI-RADS score ≤ 3\n\nExclusion Criteria\n\n* Age ≤ 30 years or \\> 85 years\n* Concurrent presence of other malignant tumors\n* Previous treatment with any form of anti-tumor therapy or prostate surgery (excluding prostate biopsy)\n* Inability to comply with PSMA PET\u002FMRI examination (e.g., contrast allergy, claustrophobia, etc.)\n* Contraindications for prostate biopsy (e.g., coagulation disorders, acute prostatitis, acute urinary tract infection, etc.)\n* Severe organ dysfunction (e.g., significant cardiac, pulmonary, hepatic, or renal impairment)\n* Incomplete clinical or pathological data","30 Years","85 Years",{"count":53,"type":23},230,[55],"NA","The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.",[29,58],"PSMA-PET",[60,61,62],"imaging examinations","PSMA PET\u002FMRI","Prostate cancer","2026-05-26",{"date":65,"type":34},"2026-05-28",{"date":67,"type":34},"2025-05-07",{"date":69,"type":23},"2026-12-01",{"name":71,"class":41},"First Affiliated Hospital of Fujian Medical University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100486024","mri-screening-in-men-at-high-risk-of-developing-prostate-cancer-100486024","NCT05608694","MRI Screening in Men at High Risk of Developing Prostate Cancer","Inclusion Criteria:\n\n* Male age 18 and older\n* No known history of prostate cancer\n* No previous prostate resection or ablation (e.g. TURP, photovaporization)\n\nExclusion Criteria:\n\n* Unable to tolerate MRI due to metal fragments or claustrophobia\n* Lack of a rectum\n* Hip arthroplasty","18 Years",{"count":81,"type":23},250,[55],"The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.",[29],"2026-02-27",{"date":87,"type":34},"2026-03-02",{"date":89,"type":34},"2022-03-02",{"date":91,"type":23},"2039-03-01",{"name":93,"class":41},"University of Chicago",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":24,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100579897","comparing-standard-of-care-biopsy-system-to-a-novel-biopsy-needle-system-by-computational-pathologic-analysis-100579897","NCT06830265","Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis","Comparing a Standard of Care Prostate Biopsy System with a Novel System Using Standard As Well As Computational Pathology Analyses to Measure Clinical and Morphometric Parameters.","Inclusion Criteria:\n\n* Adult males with PSA density greater than or equal to 0.15\n* Lesions are visible under MRI\n* PIRADS score is greater than or equal to 3\n* Able to and willing to provide consent\n\nExclusion Criteria:\n\n* Subject has had previous local prostate therapy, focal therapy, brachytherapy, ADT, surgery, or chemotherapy for prostate cancer\n* History of dementia, cognitive impairment, or deep vein thrombosis (DVT)\n* Is a prisoner currently or has a history of incarceration\n* Unable to understand English\n* Has metastatic prostate cancer or a tumor stage of T2c, T3, or T4\n* Has concurrent malignancies\n* Is positive for HIV, HBV, and\u002For HCV infection\n* Has low-performance status",{"count":103,"type":23},20,[55],"Prostate biopsy is the definitive examination to establish the diagnosis of prostate cancer, but up to 40% of these biopsies overestimate or underestimate the severity of the disease. A novel biopsy needle system captures substantially more tissue than standard of care needles, but it is important to assess the retrieval of tissue for pathologic analyses. This study will compare quality and quantity of tissue retrieved by both systems. Further, tissue will be analyzed using computational pathology algorithms for atypical small acinar proliferation and Gleason scores in terms of tissue area, tissue length, and tissue tortuosity.",[29],"NOT_YET_RECRUITING","2025-02-11",{"date":110,"type":34},"2025-02-17",{"date":112,"type":23},"2025-02-15",{"date":114,"type":23},"2026-01-10",{"name":116,"class":117},"Uro-1 Medical","INDUSTRY"]